| Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses E Piotrowska, J Jakobkiewicz-Banecka, S Barańska, A Tylki-Szymańska, ... European Journal of Human Genetics 14 (7), 846-852, 2006 | 232 | 2006 |
| Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients E Piotrowska, J Jakóbkiewicz-Banecka, A Tylki-Szymanska, A Liberek, ... Current therapeutic research 69 (2), 166-179, 2008 | 143 | 2008 |
| Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal … J Jakóbkiewicz-Banecka, E Piotrowska, M Narajczyk, S Barańska, ... Journal of Biomedical Science 16, 1-9, 2009 | 142 | 2009 |
| Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases K Pierzynowska, L Gaffke, Z Cyske, M Puchalski, E Rintz, M Bartkowski, ... Metabolic Brain Disease 33, 989-1008, 2018 | 90 | 2018 |
| Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients E Piotrowska, J Jakobkiewicz-Banecka, A Maryniak, A Tylki-Szymanska, ... Medical Science Monitor: international medical journal of experimental and …, 2011 | 82 | 2011 |
| Genistein: a natural isoflavone with a potential for treatment of genetic diseases G Węgrzyn, J Jakobkiewicz-Banecka, M Gabig-Cimińska, E Piotrowska, ... Biochemical Society Transactions 38 (2), 695-701, 2010 | 74 | 2010 |
| How close are we to therapies for Sanfilippo disease? L Gaffke, K Pierzynowska, E Piotrowska, G Węgrzyn Metabolic brain disease 33, 1-10, 2018 | 64 | 2018 |
| Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different? G Węgrzyn, J Jakóbkiewicz-Banecka, M Narajczyk, A Wiśniewski, ... Medical Hypotheses 75 (6), 605-609, 2010 | 64 | 2010 |
| Glycosaminoglycans and mucopolysaccharidosis type III J Jakobkiewicz-Banecka, M Gabig-Ciminska, A Kloska, M Malinowska, ... Front Biosci (Landmark Ed) 21 (7), 1393-409, 2016 | 59 | 2016 |
| Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression‐targeted isoflavone therapy (GET IT) J Marucha, A Tylki‐Szymańska, J Jakóbkiewicz‐Banecka, E Piotrowska, ... American Journal of Medical Genetics Part A 155 (9), 2257-2262, 2011 | 59 | 2011 |
| Female Fabry disease patients and X-chromosome inactivation P Juchniewicz, A Kloska, A Tylki-Szymańska, J Jakóbkiewicz-Banecka, ... Gene 641, 259-264, 2018 | 57 | 2018 |
| Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis E Piotrowska, J Jakóbkiewicz‐Banecka, A Tylki‐Szymańska, ... Acta Pædiatrica 98 (4), 743-749, 2009 | 49 | 2009 |
| Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis J Mantej, K Polasik, E Piotrowska, S Tukaj Cell Stress and Chaperones 24 (1), 283-287, 2019 | 48 | 2019 |
| The role of dimethyl sulfoxide (DMSO) in gene expression modulation and glycosaminoglycan metabolism in lysosomal storage disorders on an example of mucopolysaccharidosis M Moskot, J Jakóbkiewicz-Banecka, A Kloska, E Piotrowska, M Narajczyk, ... International journal of molecular sciences 20 (2), 304, 2019 | 47 | 2019 |
| Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression‐targeted isoflavone therapy E Piotrowska, J Jakóbkiewicz‐Banecka, G Węgrzyn Phytotherapy Research 24 (S1), S109-S113, 2010 | 42 | 2010 |
| Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy G Wegrzyn, A Tylki-Szymanska, A Liberek, E Piotrowska, ... American journal of medical genetics. Part A 143 (16), 1925, 2007 | 35 | 2007 |
| Molecular analysis of mucopolysaccharidosis type VI in Poland, Belarus, Lithuania and Estonia A Jurecka, E Piotrowska, L Cimbalistiene, N Gusina, A Sobczyńska, ... Molecular Genetics and Metabolism 105 (2), 237-243, 2012 | 33 | 2012 |
| Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses M Malinowska, J Jakóbkiewicz-Banecka, A Kloska, A Tylki-Szymańska, ... European journal of pediatrics 167, 203-209, 2008 | 33 | 2008 |
| Mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome) with a predominantly cardiac phenotype A Jurecka, A Golda, V Opoka-Winiarska, E Piotrowska, ... Molecular Genetics and Metabolism 104 (4), 695-699, 2011 | 31 | 2011 |
| Substrate reduction therapies for mucopolysaccharidoses J Jakóbkiewicz-Banecka, E Piotrowska, M Gabig-Ciminska, E Borysiewicz, ... Current pharmaceutical biotechnology 12 (11), 1860-1865, 2011 | 30 | 2011 |
